NEWARK, Del. — The global oral GLP-1 receptor agonist market is projected to increase from USD 1.7 billion in 2026 to USD 6.7 billion by 2036, advancing at a 14.7% CAGR, according to Future Market Insights. The market was valued at USD 1.5 billion in 2025, with forecast growth reflecting expanding oral treatment options for obesity and type 2 diabetes. FMI estimates an additional USD 5.0 billion in market revenue between 2026 and 2036.
The commercial focus is shifting beyond injectable medicines as oral formulations offer another route for eligible patients. In April 2026, Eli Lilly received U.S. approval for Foundayo (orforglipron), while Novo Nordisk had introduced Wegovy tablets through U.S. pharmacy and direct-access channels in January 2026. These developments are expanding the range of oral treatment options, although approval, patient eligibility, prescription requirements, and coverage continue to determine access.
👉 Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends:
https://www.futuremarketinsights.com/reports/sample/rep-gb-35762
Where Growth Is Fastest
- France: The market is forecast to grow at an 5% CAGR from 2026 to 2036, the fastest rate among the countries profiled by FMI. Structured obesity-care pathways and an expanding network of specialist centers are supporting treatment evaluation.
- United Kingdom: Demand is projected to rise at a 2% CAGR. The Medicines and Healthcare products Regulatory Agency authorized orforglipron in August 2026 for weight management and type 2 diabetes, widening the range of oral options. NHS access and reimbursement will remain important variables.
- Japan: The market is expected to expand at a 8% CAGR, supported by established physician experience with oral semaglutide and a substantial population living with diabetes. Broader obesity use depends on the relevant Japanese authorization and reimbursement arrangements.
- United States: The market is forecast to grow at a 4% CAGR. Commercial availability of oral semaglutide and orforglipron is expanding prescription choice, while insurance coverage and prior authorization can still limit access.
- Germany: Sales are projected to rise at an 8% CAGR. Adoption will depend on approved indications, reimbursement decisions, and the availability of authorized oral products.
What Leads the Market
- Peptide oral GLP-1 agonists: This category is projected to hold 2% of market revenue in 2026, supported by established oral semaglutide tablets and physician familiarity with gradual dose escalation.
- Obesity and weight management: This indication is expected to account for 4% of demand in 2026, reflecting the expansion of oral medicines into weight-management treatment alongside their use in diabetes care.
- Retail pharmacies: Pharmacies are projected to represent 5% of distribution-channel revenue in 2026. Prescription dispensing, access to different strengths, and repeat refills make them a central route to market.
- Home care settings: This end-user category is expected to account for 6% of revenue in 2026, as daily tablets are generally self-administered at home while physicians supervise dose changes, tolerability, and treatment response.
The Hurdle
Treatment access remains a major constraint. High out-of-pocket costs, reimbursement restrictions, and prior-authorization requirements can prevent eligible patients from starting or continuing treatment. Formulation-specific instructions also matter: oral semaglutide requires fasting-related administration steps, while orforglipron has different food and water requirements.
In December 2025, the UK medicines regulator warned about the risk of medication errors during the transition to a new Rybelsus formulation because tablet strengths were not equivalent. Such differences make accurate prescribing, patient counseling, and pharmacy processes important to continued market growth.
👉 Access the Complete Report in PDF Format:
https://www.futuremarketinsights.com/reports/brochure/rep-gb-35762
Industry Investment and Recent Developments
- September 2026: Structure Therapeutics reported up to 2% mean weight reduction at 72 weeks for aleniglipron and continued Phase 3 enrollment. The candidate remains in development; the results do not establish an approved treatment.
- April 2026: Eli Lilly received U.S. approval for Foundayo and began supply through retail pharmacies, telehealth, and direct channels.
- January 2026: Novo Nordisk made Wegovy tablets available in the United States through pharmacy and direct-access channels, extending the commercial availability of oral semaglutide for weight management.
FMI profiles Novo Nordisk, Eli Lilly and Company, Pfizer, AstraZeneca, Roche, Structure Therapeutics, Viking Therapeutics, and Kailera Therapeutics, alongside licensing-linked developers Jiangsu Hengrui Pharmaceuticals and Jiangsu Hansoh Pharmaceutical. The market includes companies with commercial oral products as well as developers whose candidates remain at clinical stages. Pfizer discontinued its danuglipron program in April 2025, underscoring the importance of clinical evidence and safety in development decisions.
Analyst View
Anurag Sharma, Principal Consultant at Future Market Insights, said:
“Oral tablets will widen weight-treatment demand where patients need simpler dosing and pharmacies can support repeat access. Small-molecule products will gain opportunity when food-flexible dosing is combined with tolerability and paid coverage.”
What This Means for Pharmaceutical Companies and Healthcare Buyers
- Differentiate on administration and treatment fit. Food requirements, dose escalation, tolerability, and the evidence supporting each medicine can influence prescribing and persistence.
- Assess access alongside clinical potential. Approval alone does not guarantee demand; reimbursement, patient eligibility, pharmacy supply, and prior authorization determine how much of the potential patient population can receive treatment.
- Separate current sales from pipeline opportunities. Oral multiagonists and other clinical-stage candidates could widen future treatment choice, but their commercial contribution depends on further evidence and regulatory decisions.
Access Full report https://www.futuremarketinsights.com/reports/oral-glp-1-receptor-agonist-market
Report Scope
The Oral GLP-1 Receptor Agonist Market report segments the market by molecule type, indication, distribution channel, and end user. Molecule categories include peptide oral GLP-1 agonists, small-molecule oral GLP-1 agonists, and oral dual and triple agonists. Indications include obesity and weight management, type 2 diabetes, and other cardiometabolic uses.
Distribution channels include retail pharmacies, online and mail-order pharmacies, and hospital pharmacies. End-user categories include home care settings, specialty endocrinology and obesity clinics, and hospitals. The report covers North America, Latin America, Western and Eastern Europe, East Asia, South Asia and the Pacific, and the Middle East and Africa, with a forecast period from 2026 to 2036.
About Future Market Insights
Future Market Insights, Inc. (FMI) is an ESOMAR-certified market research and consulting firm headquartered in Delaware, USA, with offices in the United Kingdom, the United Arab Emirates and India. FMI delivers syndicated and custom research across food and beverage, healthcare, chemicals, technology, packaging, consumer goods and industrial sectors.
Media Contact
Future Market Insights, Inc.
Phone: +1-347-918-3531
